Search clinical trials for: Quadrivalent Influenza mRNA Vaccine MRT5407

Total 1288 results

Tan Tock Seng Hospital
KK Women's and Children's Hospital; Duke-NUS Graduate Medical School; A*Star

Recruiting

Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC] (PRIBIVAC)

COVID-19

Singapore
VaxInnate Corporation

Unknown

Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years

Influenza

Australia
Sanofi

Completed

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above

Influenza

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.

Influenza Immunization

United States, Poland, Spain, Czechia
Sanofi

Completed

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months

Influenza

Korea, Republic of
Seqirus

Completed

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age

Influenza

Turkey, Philippines, Thailand, Malaysia, Lithuania, Colombia, Czechia, Estonia, Bulgaria, Latvia, Poland, Romania
GlaxoSmithKline

Completed

A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

Respiratory Syncytial Virus Infections

Finland, Spain, Canada, United States, Korea, Republic of
Kaiser Permanente
Sanofi Pasteur, a Sanofi Company

Completed

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Stroke | Pneumonia | Influenza | Congestive Heart Failure | Acute Myocardial Infarction | Lower Respiratory Tract Infection

United States
University Hospital, Ghent
CEVAC Core Lab, University Ghent; Max Planck Institute for Infection Biology... and other collaborators

Completed

Study of Biomarkers of Immune Activation Associated With Symptoms and Immune Responses After Influenza Vaccination in Adults

Prevention of Influenza

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

Japan
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort (SLVP033)

Hepatitis A | Influenza | Healthy Adults | Typhoid

United States
CureVac

Active, not recruiting

Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma

Glioblastoma

Belgium, Germany, Netherlands
Sheba Medical Center
ModernaTX, Inc.

Completed

Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults (SH-MO-214)

COVID-19 | SARS CoV 2 Infection | COVID-19 Pandemic | Immunogenicity

Israel
Janssen Research & Development, LLC

Active, not recruiting

A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older (Engage)

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

United States, Poland, Belgium, Canada
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

Herpes Zoster

Germany, Canada, United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years

Influenza

Korea, Republic of
Hualan Biological Bacterin Co. Ltd.

Completed

Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.

GCP

China
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children

Influenza

Spain, Taiwan, Canada, United States, Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

France, Belgium, Germany, Italy, Netherlands, Poland
Masonic Cancer Center, University of Minnesota

Terminated

Influenza Vaccine Post Allogeneic Transplant

Hematologic Malignancy | Hematopoietic Stem Cell Transplant

United States
Carlo Contreras

Recruiting

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Metastatic Melanoma | Clinical Stage I Cutaneous Melanoma AJCC v8 | Clinical Stage IA Cutaneous Melanoma AJCC v8 | Clinical Stage IB Cutaneous Melanoma AJCC v8 | Clinical Stage II Cutaneous Melanoma AJCC v8 | Clinical Stage IIA Cutaneous Melanoma AJCC v8 | Clinical Stage IIB Cutaneous Melanoma... and other conditions

United States
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age (RSVictory)

Respiratory Syncytial Virus

United States
ANRS, Emerging Infectious Diseases
LinKinVax; Vaccine Research Institute (VRI), France

Recruiting

Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

COVID-19

France
Seqirus

Active, not recruiting

Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying mRNA Influenza Vaccine in Healthy Adults

Influenza, Human

Australia
University of Rochester
National Institutes of Health (NIH)

Withdrawn

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children (H1N1Children)

2009 H1N1 Influenza

United States
GlaxoSmithKline

Active, not recruiting

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults

COVID-19

United States
Medicago

Completed

Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States
Medicago

Completed

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States
University of Rochester
National Institutes of Health (NIH); Dartmouth-Hitchcock Medical Center

Completed

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

Influenza

United States
Duke University
Centers for Disease Control and Prevention; Kaiser Permanente

Completed

Fever After Simultaneous Versus Sequential Vaccination in Young Children

Fever | Febrile Seizure | Fever After Vaccination

United States
Medicago

Completed

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States, Canada, Finland, Germany, Thailand
Osivax
Novotech (Australia) Pty Limited; Harmony Clinical Research; Northern Beaches...

Completed

Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.

Influenza

Australia
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above

Influenza

Germany
Green Cross Corporation

Unknown

A Study to Evaluate Efficacy and Safety of GC3110B in Healthy Adults

Influenza, Human
Sinovac Research and Development Co., Ltd.

Completed

Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine

COVID-19 | Influenza

China
Karolinska University Hospital
Karolinska Institutet

Active, not recruiting

COVID-19 Vaccination of Immunodeficient Persons (COVAXID) (COVAXID)

Covid19

Sweden
China National Biotec Group Company Limited
Peking University; Wuhan Institute of Biological Products Co., Ltd; Guizhou Center... and other collaborators

Completed

Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine

Enterovirus Infections | Influenza

China
Seqirus
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older

Influenza

Belgium
Vanderbilt University Medical Center

Completed

Senescent Immunity in Elders and Vaccine Responses (SILVER)

Flu Vaccine

United States
Medicago

Completed

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

Canada
Oriol Manuel
University of Zurich; University Hospital, Geneva; University Hospital, Basel... and other collaborators

Completed

Reducing the Burden of Influenza After Solid-Organ Transplantation (STOP-FLU)

Influenza | Organ Transplantation

Switzerland, Spain
Novartis Vaccines

Completed

Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines

Influenza

Switzerland
International AIDS Vaccine Initiative
Emory University; Fred Hutchinson Cancer Center; George Washington University; ModernaTX... and other collaborators

Active, not recruiting

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

Hiv

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

Influenza

United States
Medicago

Completed

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Influenza

United States, Canada, Finland, Germany, Philippines, Thailand, United Kingdom
Novartis
Novartis Vaccines

Completed

Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine

Influenza Infection

Switzerland
Medicago

Completed

Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States, Canada
Fluart Innovative Vaccine Ltd, Hungary

Completed

Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons

Influenza

Hungary
Methodist Health System

Completed

COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose

COVID-19 | COVID-19 Pneumonia

United States
Novavax

Terminated

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

Influenza, Human

United States

3

Subscribe